Melanoma in Solid Organ Transplant Recipients

[1]  J. Sosman,et al.  Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy , 2020, Journal of immunotherapy.

[2]  V. Sondak,et al.  Systemic Therapy for Melanoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Austin,et al.  Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. , 2020, Journal of the American Academy of Dermatology.

[4]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  C. Vajdic,et al.  Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria, Australia. , 2019, Journal of the American Academy of Dermatology.

[6]  D. Hesselink,et al.  Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment , 2019, Journal of Immunotherapy for Cancer.

[7]  M. Suarez‐Almazor,et al.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[8]  Jennifer Y. Lin,et al.  Cutaneous Melanoma-A Review in Detection, Staging, and Management. , 2019, Hematology/oncology clinics of North America.

[9]  John C. Su,et al.  Skin Cancer Following Solid Organ Transplantation: A Review of Risk Factors and Models of Care , 2018, American Journal of Clinical Dermatology.

[10]  D. Hogg,et al.  Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. , 2018, Melanoma research.

[11]  E. Decullier,et al.  Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  A. Toland,et al.  Epidemiology of keratinocyte carcinomas after organ transplantation , 2017, The British journal of dermatology.

[13]  B. Dréno,et al.  Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. , 2017, Acta dermato-venereologica.

[14]  N. Karanth,et al.  Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report , 2017, Journal of Medical Case Reports.

[15]  J. Stein,et al.  Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States , 2017, JAMA dermatology.

[16]  K. Jhaveri,et al.  Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. , 2017, The New England journal of medicine.

[17]  D. Schadendorf,et al.  Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. , 2016, European journal of cancer.

[18]  H. Denley,et al.  Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. , 2016, Transplantation proceedings.

[19]  G. Knoll,et al.  Antitumor activity of nivolumab on hemodialysis after renal allograft rejection , 2016, Journal of Immunotherapy for Cancer.

[20]  U. Maggiore,et al.  The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. , 2016, Advances in Chronic Kidney Disease.

[21]  C. Boils,et al.  Use of the PD‐1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  J. Larkin,et al.  Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  I. Pastushenko,et al.  Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. , 2016, Actas dermo-sifiliograficas.

[24]  G. Koehl,et al.  Cyclosporine A Inhibits the T‐bet–Dependent Antitumor Response of CD8+ T Cells , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  G. Linette,et al.  Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  J. Taube,et al.  Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. , 2016, The New England journal of medicine.

[27]  S. Arron,et al.  Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC) , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  C. McCulloch,et al.  Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma , 2016, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[29]  R. Gutzmer,et al.  BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma. , 2016, JAMA dermatology.

[30]  Rosie Qin,et al.  Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. , 2015, Melanoma management.

[31]  Steven He,et al.  Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature , 2015, JAAD case reports.

[32]  S. Arron,et al.  Melanoma risk and survival among organ transplant recipients , 2015, The Journal of investigative dermatology.

[33]  B. Rozell,et al.  Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality. , 2015, Journal of the American Academy of Dermatology.

[34]  E. Lipson,et al.  Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation , 2015, Journal of Immunotherapy for Cancer.

[35]  T. Panella,et al.  Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. , 2015, Journal of immunotherapy.

[36]  E. Geissler.  Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? , 2015, Transplantation research.

[37]  G. Knoll,et al.  Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data , 2014, BMJ : British Medical Journal.

[38]  E. Lipson,et al.  Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Arron,et al.  Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  A. Hauschild,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Brewer,et al.  Melanoma in immunosuppressed patients. , 2012, Mayo Clinic proceedings.

[42]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[43]  F. Schena,et al.  Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial , 2011, Transplantation.

[44]  A. Weaver,et al.  Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. , 2011, Archives of dermatology.

[45]  J. Brewer.  Melanoma in immunosuppressed patients , 2010 .

[46]  D Ratner,et al.  Melanoma in Solid Organ Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  Jean Kanitakis,et al.  BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. , 2010, European journal of dermatology : EJD.

[48]  A. Webster,et al.  Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[49]  J. McGregor,et al.  Prognosis of Pretransplant Melanoma , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[50]  J. Bouwes Bavinck,et al.  Melanoma in Organ Transplant Recipients: Clinicopathological Features and Outcome in 100 Cases , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  A. Weaver,et al.  Outcomes of melanoma in recipients of solid organ transplant. , 2008, Journal of the American Academy of Dermatology.

[52]  R. Matin,et al.  Melanomas in renal transplant recipients: the London experience, and invitation to participate in a European study* , 2007, The British journal of dermatology.

[53]  F. Wojnarowska,et al.  Melanomas in renal transplant recipients , 2006, The British journal of dermatology.

[54]  J. Garcés,et al.  Reduction of immunosuppression for transplant‐associated skin cancer: expert consensus survey , 2006, The British journal of dermatology.

[55]  C. Hollenbeak,et al.  Increased incidence of melanoma in renal transplantation recipients , 2005, Cancer.

[56]  Jean Kanitakis,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[57]  G. Parmiani,et al.  T‐cell recognition of melanoma‐associated antigens , 2000 .

[58]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[59]  I. Penn.  Malignant melanoma in organ allograft recipients. , 1996, Transplantation.

[60]  J. Cañueto,et al.  Los nuevos sistemas de estadificación del AJCC incorporan novedades en el cáncer cutáneo , 2020 .

[61]  O. Viklicky,et al.  Malignant melanoma in organ transplant recipients: incidence, outcomes, and management strategies: a review of literature , 2016, Dermatologic therapy.

[62]  S. Vlajković,et al.  Primary mucosal melanomas: a comprehensive review. , 2012, International journal of clinical and experimental pathology.

[63]  B. Thiers.  Increased Incidence of Melanoma in Renal Transplantation Recipients , 2006 .